

References

- A. Michael Lincoff, Kirstine Brown-Frandsen, Colhoun, H. M., Deanfield, J., Emerson, S. S., Sille Esbjerg, Søren Hardt-Lindberg, G. Kees Hovingh, Kahn, S. E., Kushner, R. F., Ildiko Lingvay, Tuğçe Kalaycı Oral, Marie Mide Michelsen, Plutzky, J., Tornøe, C. W., & Ryan, D. H. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. *The New England Journal of Medicine*, 389(24).
<https://doi.org/10.1056/nejmoa2307563>
- Bethel, M. A., Patel, R. A., Merrill, P., Lokhnygina, Y., Buse, J. B., Mentz, R. J., Pagidipati, N. J., Chan, J. C., Gustavson, S. M., Iqbal, N., Maggioni, A. P., Öhman, P., Poulter, N. R., Ramachandran, A., Zinman, B., Hernandez, A. F., & Holman, R. R. (2018). Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. *The Lancet Diabetes & Endocrinology*, 6(2), 105–113.
[https://doi.org/10.1016/s2213-8587\(17\)30412-6](https://doi.org/10.1016/s2213-8587(17)30412-6)
- Bettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J., & Nauck, M. A. (2016). Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. *Diabetes, Obesity and Metabolism*, 19(3), 336–347.
<https://doi.org/10.1111/dom.12824>
- Brito, J. P., Herrin, J., Kavya Sindhu Swarna, Singh, M., Montori, V. M., Toro-Tobon, D., Umpierrez, G. E., Galindo, R. J., Deng, Y., Mickelson, M. M., Shao, H., Polley, E. C., & McCoy, R. G. (2025). GLP-1RA Use and Thyroid Cancer Risk. *JAMA Otolaryngology–Head & Neck Surgery*. <https://doi.org/10.1001/jamaoto.2024.4852>
- Calderon, A., Santos, A., & Luo, H. (2022). #1302161: Mechanism Behind GLP1RA-Induced

Refractory Tachycardia: A Case and Literature Review. *Endocrine Practice*, 28(12), S7.

<https://doi.org/10.1016/j.eprac.2022.10.169>

Castro, R. (2022, June 29). *Diabetes Drugs and Weight Loss*. Mayo Clinic.

<https://www.mayoclinic.org/diseases-conditions/type-2-diabetes/expert-answers/byetta/faq-20057955>

Catanese, L. (2024, February 5). *GLP-1 diabetes and weight-loss drug side effects*: Harvard Health.

<https://www.health.harvard.edu/staying-healthy/ghp-1-diabetes-and-weight-loss-drug-side-effects-ozempic-face-and-more>

Chis, B. A., & Fodor, D. (2018). Acute pancreatitis during GLP-1 receptor agonist treatment. A case report. *Medicine and Pharmacy Reports*, 91(1), 117–119.

<https://doi.org/10.15386/cjmed-804>

Cleveland Clinic. (2022). *Glucagon: What It Is, Function & Symptoms*. Cleveland Clinic.

<https://my.clevelandclinic.org/health/articles/22283-glucagon>

Cleveland Clinic. (2023a). *Type 2 diabetes*. Cleveland Clinic.

<https://my.clevelandclinic.org/health/diseases/21501-type-2-diabetes>

Cleveland Clinic. (2023b, July 3). *GLP-1 Agonists*. Cleveland Clinic; Cleveland Clinic.

<https://my.clevelandclinic.org/health/treatments/13901-ghp-1-agonists>

Cleveland Clinic. (2024, January 17). *Insulin*. Cleveland Clinic; Cleveland Clinic.

<https://my.clevelandclinic.org/health/body/22601-insulin>

Collins, L., & Costello, R. A. (2024, February 29). *Glucagon-like peptide-1 receptor agonists*.

PubMed; StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK551568/>

Cooper, D. M., Rothstein, M. A., Amin, A., Hirsch, J. E., & Cooper, E. M. (2023). Unintended

consequences of glucagon-like peptide-1 receptor agonists medications in children and adolescents: A call to action. *Journal of Clinical and Translational Science*, 7(1).

<https://doi.org/10.1017/cts.2023.612>

Dankner, R., Murad, H., Agay, N., Olmer, L., & Freedman, L. S. (2024). Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients With Type 2 Diabetes. *JAMA Network Open*, 7(1), e2350408.

<https://doi.org/10.1001/jamanetworkopen.2023.50408>

Drucker, Daniel J. (2016). The Cardiovascular Biology of Glucagon-like Peptide-1. *Cell Metabolism*, 24(1), 15–30. <https://doi.org/10.1016/j.cmet.2016.06.009>

Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2015). Adverse Effects of GLP-1 Receptor Agonists. *The Review of Diabetic Studies*, 11(3-4), 202–230.

<https://doi.org/10.1900/rds.2014.11.202>

Fong, S., Carollo, A., Lazuras, L., Corazza, O., & Esposito, G. (2024). Ozempic (Glucagon-like peptide 1 receptor agonist) in Social Media Posts: Unveiling User Perspectives through Reddit Topic Modeling. *Emerging Trends in Drugs Addictions and Health*, 4,

100157–100157. <https://www.sciencedirect.com/science/article/pii/S2667118224000163>

Ghusn, W., & Hurtado, M. D. (2024). Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks. *Obesity Pillars*, 12, 100127.

<https://doi.org/10.1016/j.obpill.2024.100127>

GLP-1 Studies Add to Growing Body of Evidence Demonstrating Significant Benefit on Cardiovascular Outcomes | SCAI. (2025). Scai.org.

<https://www.scai.org/media-center/news-and-articles/glp-1-studies-add-growing-body-evidence-demonstrating-significant>

Gluud, L. L. (2023). GLP-1 Receptor Agonists for Weight Loss in People without Type 2 Diabetes: What is the Current Evidence? *The American Journal of Clinical Nutrition*, 118(3), 494–495. [https://ajcn.nutrition.org/article/S0002-9165\(23\)66031-9/fulltext](https://ajcn.nutrition.org/article/S0002-9165(23)66031-9/fulltext)

Goodacre, S. (2025). *The Benefits and Risks of Microdosing GLP-1s - EVEXIAS Health Solutions*. EVEXIAS Health Solutions.
<https://www.evexias.com/the-benefits-and-risks-of-microdosing-glp-1s>

Karagiannis, T., Bekiari, E., & Apostolos Tsapas. (2023). Socioeconomic aspects of incretin-based therapy. *Diabetologia*. <https://doi.org/10.1007/s00125-023-05962-z>

KHADKE, S., KUMAR, A., BHATTI, A., DANI, S. S., AL-KINDI, S., NASIR, K., VIRANI, S. S., UPADHYAY, J., GARCIA-BANIGAN, D. C., ABRAHAM, S., HUSAMI, R., KONG, Y., LABIB, S., VENESY, D., SHAH, S., LENIHAN, D., VADUGANATHAN, M., DESWAL, A., FONAROW, G. C., & BUTLER, J. (2024). GLP-1 Receptor Agonist in Nonobese Patients with Type 2 Diabetes Mellitus and Heart Failure with Preserved Ejection Fraction. *Journal of Cardiac Failure*.
<https://doi.org/10.1016/j.cardfail.2024.10.448>

Lamija Ferhatbegović, Mršić, D., & Amra Macić-Džanković. (2023). The benefits of GLP1 receptors in cardiovascular diseases. *Frontiers in Clinical Diabetes and Healthcare*, 4.
<https://pmc.ncbi.nlm.nih.gov/articles/PMC10739421/>

Latif, W., Lambrinos, K. J., & Rodriguez, R. (2024, February 25). *Compare And Contrast the Glucagon-like Peptide-1 Receptor Agonists (GLP1RAs)*. PubMed; StatPearls Publishing.
<https://www.ncbi.nlm.nih.gov/books/NBK572151/>

Lin, C., Chen, J., Meyerowitz-Katz, G., Huang, Y., & Su, P. (2025). Unexpected cardiovascular risks of glucagon-like peptide-1 receptor agonist and aspirin co-administration in

individuals with obesity, with and without type 2 diabetes: A propensity score matched cohort study. *Diabetes, Obesity and Metabolism*, 27(4), 1980–1991.

<https://doi.org/10.1111/dom.16191>

Lisco, G., Anna De Tullio, Disoteco, O., Piazzolla, G., Edoardo Guastamacchia, Sabbà, C., Vincenzo De Geronimo, Papini, E., & Triggiani, V. (2023). Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned? *Endocrine Connections*, 12(11). <https://doi.org/10.1530/ec-23-0257>

Marx, N., Husain, M., Lehrke, M., Verma, S., & Sattar, N. (2022). GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes. *Circulation*, 146(24), 1882–1894.

<https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.059595>

Meline, M. (2024, October 17). *Key Lessons for Ethical and Affordable Access to GLP-1 Drugs*. Penn LDI.

<https://ldi.upenn.edu/our-work/research-updates/key-lessons-for-ethical-and-affordable-access-to-glp-1-drugs-like-ozempic-and-wegovy/>

Michos, E. D., Bakris, G. L., Rodbard, H. W., & Tuttle, K. R. (2023). Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection. *American Journal of Preventive Cardiology*, 14, 100502.

<https://doi.org/10.1016/j.ajpc.2023.100502>

Moiz, A., Fillion, K. B., Toutounchi, H., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025). Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials. *Annals of Internal Medicine*,

10.7326/ANNALS24-01590. <https://doi.org/10.7326/ANNALS-24-01590>

Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., Holst, J. J., Langhans, W., Meier, J. J., Nauck, M. A., Perez-Tilve, D., Pocai, A., Reimann, F., Sandoval, D. A., Schwartz, T. W., & Seeley, R. J. (2019). Glucagon-like peptide 1 (GLP-1). *Molecular Metabolism*, 30, 72–130. <https://doi.org/10.1016/j.molmet.2019.09.010>

Nauck, M. A., & Meier, J. J. (2018). Incretin hormones: Their role in health and disease. *Diabetes, Obesity & Metabolism*, 20 Suppl 1(S1), 5–21. <https://doi.org/10.1111/dom.13129>

Neerav Mullur, Morissette, A., Morrow, N., & Mulvihill, E. (2024). GLP-1 receptor agonist-based and cardiovascular risk: a review of mechanisms. *Journal of Endocrinology*. <https://doi.org/10.1530/joe-24-0046>

Niewijk, G. (2024, May 30). *Research shows GLP-1 receptor agonist drugs are effective but come with complex concerns*. Uchicagomedicine.org; UChicago Medicine. <https://www.uchicagomedicine.org/forefront/research-and-discoveries-articles/research-on-glp-1-drugs>

Okerson, T., & Chilton, R. J. (2010). The Cardiovascular Effects of GLP-1 Receptor Agonists. *Cardiovascular Therapeutics*, 30(3), e146–e155. <https://pubmed.ncbi.nlm.nih.gov/21167014/>

Priyanjana Pramanik, MSc. (2024, May 29). *News-Medical*. News-Medical. <https://www.news-medical.net/news/20240529/GLP-1-receptor-agonists-effective-for-weight-loss-in-obesity-without-diabetes.aspx>

Qualifying for GLP-1 Weight Loss: Who's a Good Candidate?: Hopkins MD: Primary Care

Practice. (2025). Hopkinsmd.com.

<https://www.hopkinsmd.com/blog/qualifying-for-glp-1-weight-loss-whos-a-good-candidate>

Rivera, F. B., Cruz, L. L. A., Magalong, J. V., Ruyeras, J. M. M. J., Aparece, J. P., Bantayan, N. R. B., Lara-Breitinger, K., & Gulati, M. (2024). Cardiovascular and Renal Outcomes of Glucagon-like Peptide 1 Receptor Agonists among patients with and without type 2 diabetes mellitus: A Meta-analysis of Randomized Placebo-Controlled Trials. *American Journal of Preventive Cardiology*, *18*, 100679.

<https://doi.org/10.1016/j.ajpc.2024.100679>

Sauerwein, K. (2025, January 20). *Study identifies benefits, risks linked to popular weight-loss drugs* | *WashU Medicine*. WashU Medicine.

<https://medicine.washu.edu/news/study-identifies-benefits-risks-linked-to-popular-weight-loss-drugs/>

Shor, R., Mihalache, A., Noori, A., Shor, R., Kohly, R. P., Popovic, M. M., & Muni, R. H. (2025). Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related Macular Degeneration. *JAMA Ophthalmology*.

<https://doi.org/10.1001/jamaophthalmol.2025.1455>

Singh, S., Garg, A., Tantry, U. S., Bliden, K., Gurbel, P. A., & Gulati, M. (2024). Safety and efficacy of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese non-diabetic patients. *Current Problems in Cardiology*, *49*(3), 102403–102403. <https://doi.org/10.1016/j.cpcardiol.2024.102403>

Tan, H. C., Dampil, O. A., & Marquez, M. M. (2022). Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.

Journal of the ASEAN Federation of Endocrine Societies, 37(2), 65–72.

<https://doi.org/10.15605/jafes.037.02.14>

- Tariq, S., Ali, M. A., Hassan Iftikhar, H. M., Fareh Ali, M., Shah, S. Q. A., Perveen, F., & Zaman, T. (2024). Long-Term Cardiovascular Outcomes of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes: A Systematic Review. *Cureus*, 16(11), e73705. <https://doi.org/10.7759/cureus.73705>
- Tseng, C.-H., Lee, K.-Y., & Tseng, F.-H. (2015). An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers. *Journal of Environmental Science and Health, Part C*, 33(1), 67–124. <https://doi.org/10.1080/10590501.2015.1003496>
- Ussher, J. R., & Drucker, D. J. (2023). Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. *Nature Reviews Cardiology*, 20(7), 463–474. <https://doi.org/10.1038/s41569-023-00849-3>
- Xu, L., & Zhu, D. (2024). GLP-1RA may have varying effects on cardiac structure in patients with ASCVD depending on BMI. *Frontiers in Endocrinology*, 15. <https://doi.org/10.3389/fendo.2024.1355540>
- Zhang, X., Shao, F., Zhu, L., Ze, Y., Zhu, D., & Bi, Y. (2018). Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis. *BMC Pharmacology and Toxicology*, 19(1). <https://doi.org/10.1186/s40360-018-0246-x>